Barclays lowered the firm’s price target on Jazz Pharmaceuticals to $230 from $235 and keeps an Overweight rating on the shares. The company’s 2024 outlook is not as bad as the stock’s 7% drop indicates, the analyst tells investors in a research note. The firm says Jazz’s incremental color on Zani’s near-term readouts “adds assurance” to the pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAZZ:
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
- Jazz Pharmaceuticals sees FY24 adjusted EPS $18.15-$19.35, consensus $19.94
- Jazz Pharmaceuticals reports Q4 adjusted EPS $5.02, consensus $5.18
- Jazz Pharmaceuticals Announces Board Changes and Appointments
- JAZZ Upcoming Earnings Report: What to Expect?
